SCA
SLDB icon

Secor Capital Advisors’s Solid Biosciences SLDB Stock Holding History

Secor Capital Advisors’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,614
Closed -$223K – 230
2019
Q1 		$223K Buy
+1,614
New +$404K 0.05% 359

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Secor Capital Advisors's SLDB Position: Q2 2019 in Review

Secor Capital Advisors sold out of Solid Biosciences (SLDB) in Q2 2019, closing a stake of 1,614 shares — an estimated $223K sold.

Secor Capital Advisors first reported a position in SLDB in Q1 2019 and held it in 1 quarter. The position peaked at $223K in Q1 2019. 74 funds tracked by Wall St. Rank hold SLDB as of Q2 2019.

  • Secor Capital Advisors reported no remaining Solid Biosciences position as of Q2 2019 after selling out during the quarter.
  • Secor Capital Advisors sold 1,614 Solid Biosciences shares in Q2 2019, an estimated $223K.
  • Secor Capital Advisors first reported a position in Solid Biosciences in Q1 2019 and held it in 1 quarter.
  • Secor Capital Advisors's Solid Biosciences position peaked at $223K in Q1 2019.
  • 74 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2019.

Based on Secor Capital Advisors's 13F filing for Q2 2019.